Company Profile
Caribou Stock Price, News & Analysis
- Ticker:
- CRBU
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.64 USD (+1.86%)
Close
Last updated: August 6, 2026
230M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRBU closed up 1.86% at $1.64. No new same-company headline was identified in the current news window.
Company overview
Allogeneic Cell Therapy
Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells.
Vispa-cel
Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T therapy with a PD-1 knockout. Development is focused on relapsed or refractory B-cell non-Hodgkin lymphoma, including a pivotal path in second-line large B-cell lymphoma.
ANTLER-3 Pivotal Strategy
The planned ANTLER-3 study is designed to establish vispa-cel as an immediately available alternative to autologous CAR-T therapy in second-line large B-cell lymphoma.
CB-011
CB-011 is an allogeneic anti-BCMA CAR-T candidate being evaluated in the Phase 1 CaMMouflage study for relapsed or refractory multiple myeloma.
Future catalysts
Longer-follow-up Phase 1 data for vispa-cel at a medical conference in 2026.
Dose-escalation and expansion data from the Phase 1 CaMMouflage study of CB-011 during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Caribou (CRBU)?
Caribou (CRBU) most recently closed at 1.64 USD, a +1.86% move versus the previous session.
What is the market cap of Caribou (CRBU)?
Caribou currently has a market capitalization of 230M USD on BioPharmSignal.
What does Caribou do?
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T...
On which exchange is CRBU stock listed?
Caribou (CRBU) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform.
Which conditions is Caribou targeting with CAR-T?
Allogeneic Cell Therapy Caribou Biosciences develops off-the-shelf CAR-T cell therapies using its CRISPR genome-editing platform. Its candidates incorporate multiple edits intended to improve persistence, antitumor activity and compatibility with donor-derived cells. Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T...
How does Caribou describe recent progress with CAR-T?
Longer-follow-up Phase 1 data for vispa-cel at a medical conference in 2026. Dose-escalation and expansion data from the Phase 1 CaMMouflage study of CB-011 during 2026.
What is PD-1?
Vispa-cel Vispacabtagene regedleucel, or vispa-cel, is an allogeneic anti-CD19 CAR-T therapy with a PD-1 knockout.